0184 Clinical experience with fulvestrant, pure oestrogen receptor (ER) antagonist with no agonist effects, in pre-treated advanced breast cancer patients

Abstract

pCR, and 4 non pCR. In the HER2 neg group, 3/20 had pCR, 1 near pCR, and 16 non pCR. Mean progranulin serum levels in HER2 pos were 45.9 (23−73), 40.2 (20−82), and 44.3 (23−96) pg/ml (range) before, after 3 and 6 cycles, respectively. For the HER2 neg, respective numbers were 59.2 (25–144), 57.9 (18–141), and 33.5 (12.2−73). Also for VEGF and PlGF, no significant changes were seen, with even a tendency for increase in PlGF after chemotherapy in both groups (p 0.0001 with Wilcoxon signed rank test). If patients with pCR were compared with those without pCR, no remarkable/significant changes in baseline VEGF/PlGF/progranulin were found, nor differences in evolution of these markers from baseline to cycle 3, but subgroups were small. Conclusion: This exploratory study does not support the hypothesis that serum levels of progranulin correlate with resistance to chemotherapy and/or trastuzumab in LABC (both HER2 pos and neg). PlGF levels seem to increase after chemotherapy; a clear explanation is not available, and further research is warranted.